The Biomet M2a hip implant failure class action involves a major medical device settlement stemming from metal-on-metal hip replacements that generated excessive metal particles and poisoned patients. In 2014, Biomet settled more than 2,800 lawsuits for $56 million due to complications from the M2a Magnum implant design, with individual settlements ranging from $10,000 to $200,000 depending on factors like revision surgery timing and implant duration.
Despite this large-scale settlement more than a decade ago, lawyers continue accepting individual Biomet M2a lawsuits in 2026, meaning eligible patients may still have legal remedies available. The core problem with the M2a design was its metal-on-metal construction, where both the femoral head and acetabular cup were made of cobalt-chromium alloy. Over time, this design produced what engineers call “wear debris”—microscopic metal particles that accumulated in the body, causing a cascade of medical complications including metallosis, pseudotumors, elevated blood metal levels, muscle and bone damage, and implant loosening.
Table of Contents
- What Complications Does the Biomet M2a Implant Cause?
- The 2014 Settlement Agreement and Payment Structure
- How Metal Particles Accumulate in the Body
- Steps for Filing a Claim or Lawsuit
- Eligibility and Timeline Considerations
- The Canadian Class Action Settlement
- Current Status and Ongoing Legal Landscape
- Conclusion
What Complications Does the Biomet M2a Implant Cause?
Patients with Biomet M2a implants experienced a range of serious medical conditions that manifested years after surgery. The primary complication was metallosis, a reaction to metal particles accumulating in tissues surrounding the implant. Laboratory analysis showed that M2a implants generated up to 1 mm³ of metal particles per million movement cycles, releasing 10¹²–10¹⁴ nanoparticles annually—particles so small (25-50 nanometers) that they penetrate deep into surrounding tissues and bloodstream. These metal particles, primarily cobalt and chromium, triggered inflammatory responses in the hip joint and surrounding muscles.
Patients developed pseudotumors—benign but problematic soft-tissue masses that compressed nerves and muscles around the hip. Blood tests often revealed dangerously elevated cobalt and chromium levels far exceeding normal ranges. Beyond these chemistry-driven complications, the wear debris weakened the bone-implant interface, causing osteolysis (bone loss) and mechanical loosening. A patient might initially experience minor pain or stiffness, only to discover years later that revision surgery was necessary because the implant no longer functioned safely.
The 2014 Settlement Agreement and Payment Structure
Biomet’s $56 million settlement addressed these widespread complications through structured compensation based on implant longevity and surgical outcomes. The settlement established that patients who underwent revision surgery at least 180 days after their initial implant received base compensation amounts of $200,000, though the actual payouts were adjusted based on how long the implant remained in place. Most patients ultimately received between $10,000 and $200,000 depending on their individual circumstances.
A crucial limitation of the 2014 settlement was that Biomet admitted no liability in reaching the agreement—the company neither conceded that the implant design was defective nor that patients were harmed by negligence. This is typical for large pharmaceutical and medical device settlements but means the legal record does not establish causation as a matter of fact. Additionally, because the settlement only covered patients within the original lawsuit claims period, any patient who discovered complications after the settlement deadline had to pursue separate litigation. This is why law firms continue accepting new Biomet M2a cases in 2026, offering a path for individuals whose claims fell outside the original settlement class.
How Metal Particles Accumulate in the Body
The mechanism behind metal particle generation in M2a implants reveals why the device design proved problematic over the long term. Metal-on-metal hip designs rely on a thin film of fluid between the bearing surfaces to reduce friction, but this fluid breaks down with age, mechanical stress, and surgical implantation factors. Once the protective film degrades, direct metal-to-metal contact accelerates wear, much like running machinery without adequate lubrication. The tribological action—the microscopic grinding at bearing surfaces—creates particles that escape into synovial fluid, migrate into bloodstream, and deposit in organs and tissues.
The particle size matters critically. Large debris particles might be cleared by the body’s immune system, but nanoparticles penetrate past normal biological barriers. A patient with an M2a implant might experience wear rates 5 to 10 times higher than conventional ceramic or plastic-on-metal designs, though individual variation was significant. Some patients developed complications within a few years while others remained asymptomatic for a decade. This unpredictability meant that even a patient who felt fine years into implantation could suddenly require emergency revision surgery when bone loss advanced beyond critical thresholds.
Steps for Filing a Claim or Lawsuit
Patients who received a Biomet M2a implant and subsequently developed complications have several pathways to compensation. First, check whether you are eligible for the original 2014 settlement by contacting Biomet or reviewing settlement documentation—though the claims period for this settlement has long passed. Second, if you miss that window, consult a personal injury attorney specializing in medical device litigation. An attorney will evaluate your medical records, implant records, and complication timeline to determine whether you have a viable individual lawsuit claim.
The process typically begins with gathering documentation: the original hip replacement surgery records, any imaging studies (X-rays, MRIs, CT scans), blood test results showing elevated metal levels, surgical reports for any revision procedures, and medical records describing complications like pain, limited mobility, or pseudotumor formation. Your attorney will likely consult with a medical expert who reviews these records and provides a causation opinion—establishing that your complications were more likely than not caused by the M2a implant rather than natural hip deterioration or other factors. This expert opinion is critical because without it, courts are unlikely to allow your case to proceed. A comparison: a patient whose M2a implant failed after three years of heavy use may have a stronger case than one whose implant lasted ten years, because the shorter timeline suggests accelerated wear rather than age-related decline.
Eligibility and Timeline Considerations
Not all hip replacement patients with M2a implants qualify for compensation. The primary eligibility factors are the implant type (M2a-38 or M2a-Magnum specifically), the timing of complications relative to implantation, and whether you developed documented medical complications. Patients who experienced revisions or removals are generally better positioned legally than those with asymptomatic implants, even if elevated blood metal levels are present. A major limitation exists around the statute of limitations: most states allow product liability claims to proceed only within a certain window (typically two to three years from discovery of the defect), so timing is critical. Waiting years after symptoms appear to consult an attorney can jeopardize your legal rights.
Another practical consideration is the burden of proof. Unlike the original settlement where compensation was streamlined, a new individual lawsuit requires your attorney to prove the M2a implant caused your specific complications—not just that M2a implants are generally problematic. This is a higher bar. You must show that your symptoms align with known M2a complications, that the timing suggests implant-related failure rather than coincidence, and that no alternative medical explanation adequately accounts for your condition. Additionally, Biomet may argue that you failed to comply with post-operative care instructions, that your body weight or activity level exceeded recommended limits, or that other factors contributed to failure. These defenses are not always successful, but they represent realistic obstacles.
The Canadian Class Action Settlement
In Canada, a separate settlement resolved claims related to Biomet hip implants with a claims period that closed on January 26, 2026. This settlement received final court approval on October 25, 2024, making it a recently finalized legal action. Like the U.S. settlement, the Canadian agreement did not require Biomet to admit liability, meaning the company neither accepted nor rejected responsibility for implant defects. Patients in Canada affected by M2a complications may have already submitted claims before the January 2026 deadline, and they are now in the waiting period for payment processing.
The existence of parallel U.S. and Canadian settlements illustrates that the M2a implant problems were recognized across borders. Healthcare regulatory agencies in both countries allowed Biomet to continue distributing the implant for years despite accumulating safety data, a pattern common in medical device regulation where devices remain on the market while litigation proceeds. An important example: a Canadian patient who had revision surgery in 2015 may have waited years to discover the settlement, only to miss the January 2026 claims deadline. This scenario highlights why ongoing legal representation is valuable—attorneys track settlement deadlines and ensure eligible clients submit claims on time.
Current Status and Ongoing Legal Landscape
As of 2026, the Biomet M2a story is not closed despite the decade-old settlement. Law firms continue to accept new individual lawsuits from patients whose claims fell outside the original settlement class or who did not meet the settlement’s strict eligibility criteria. This reflects a broader reality: large settlements rarely resolve all potential claims, particularly when the statute of limitations allows late-discovered injuries to be pursued independently. The fact that lawyers remain active in this space suggests they believe viable cases still exist and juries remain sympathetic to plaintiffs injured by defective medical devices.
Looking forward, the long-term medical and legal implications of metal-on-metal hip implants continue to unfold. Regulatory agencies have become more cautious about metal-on-metal designs, and newer hip implant technology has shifted toward ceramic-on-ceramic and ceramic-on-plastic bearings with lower wear rates. Patients with aging M2a implants face ongoing uncertainty about whether their devices will continue functioning or require eventual revision surgery. The Biomet M2a experience serves as a cautionary chapter in medical device safety, demonstrating how design flaws can remain hidden for years before complications surface and litigation follows.
Conclusion
The Biomet M2a hip implant class action represents one of the significant product liability settlements in orthopedic medicine. The 2014 settlement of $56 million addressed metal poisoning and complications in over 2,800 patients, with individual payouts ranging from $10,000 to $200,000. However, this settlement was not the final word—eligible patients whose claims emerged after the settlement deadline or who did not meet specific criteria may still pursue individual litigation in 2026.
If you received a Biomet M2a implant and subsequently developed hip pain, limited mobility, elevated metal blood levels, or pseudotumor complications, consult a medical device attorney promptly. The statute of limitations constrains how long you can wait to file, and strong cases require timely medical documentation and expert review. The experience with Biomet M2a implants underscores the importance of staying informed about medical device recalls and settlements, and advocating for yourself if you suspect your implant is failing.